Share on StockTwits

Ladenburg Thalmann hoisted their price objective on shares of BioDelivery Sciences International (NASDAQ:BDSI) to $21.00 in a research note issued on Wednesday. The firm currently has a “buy” rating on the stock. Ladenburg Thalmann’s target price points to a potential upside of 50.65% from the stock’s previous close.

A number of other analysts have also recently weighed in on BDSI. Analysts at Roth Capital raised their price target on shares of BioDelivery Sciences International from $15.50 to $16.50 in a research note on Monday. Finally, analysts at Laidlaw reiterated a “buy” rating on shares of BioDelivery Sciences International in a research note on Monday, June 9th. They now have a $15.00 price target on the stock. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $19.92.

Shares of BioDelivery Sciences International (NASDAQ:BDSI) traded up 8.48% during mid-day trading on Wednesday, hitting $13.94. 2,276,129 shares of the company’s stock traded hands. BioDelivery Sciences International has a 52 week low of $4.15 and a 52 week high of $14.38. The stock has a 50-day moving average of $11.1 and a 200-day moving average of $8.82. The company’s market cap is $675.3 million.

BioDelivery Sciences International (NASDAQ:BDSI) last issued its quarterly earnings data on Friday, May 9th. The company reported ($0.11) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.15) by $0.04. The company had revenue of $20.69 million for the quarter, compared to the consensus estimate of $11.60 million. On average, analysts predict that BioDelivery Sciences International will post $-0.65 earnings per share for the current fiscal year.

BioDelivery Sciences International, Inc (NASDAQ:BDSI) is a specialty pharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.